Actively Recruiting
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Led by Hebei Medical University Fourth Hospital · Updated on 2025-12-11
75
Participants Needed
1
Research Sites
352 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an prospective, multicenter, single-arm clinical study.
CONDITIONS
Official Title
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Signed informed consent and willing to follow study requirements
- Histopathologically confirmed HER2-negative invasive breast cancer, including triple-negative or luminal types (ER/PR positive and HER2 negative)
- HER2 negative defined as 0/1+ on IHC test; HER2/CEP17 ratio below 2.0 or HER2 gene copy number less than 4
- ER positive and/or PR positive defined as at least 1% positive tumor cells
- AJCC 8th edition TNM stage II to IIIC (T2-T4 plus any N, or any T plus N1-3, M0)
- Adequate organ function with hemoglobin 90 g/L, neutrophils 1.5x10^9/L, platelets 100x10^9/L, leukocytes 3.0x10^9/L
- Total bilirubin less than 1.5 times upper limit of normal (ULN)
- Creatinine less than 1.5 times ULN
- AST/ALT less than 1.5 times ULN
- Cardiac ultrasound showing left ventricular ejection fraction (LVEF) 55%
- Investigator assessment of suitability for bevacizumab treatment
You will not qualify if you...
- Stage IV (metastatic) breast cancer
- Prior treatment for breast cancer including chemotherapy, endocrine therapy, radiotherapy, or immunotherapy
- Participation in other intervention studies
- Women who are pregnant or breastfeeding
- Serious concurrent diseases that endanger safety or affect study completion, as judged by investigator
- Other reasons deemed unsuitable for inclusion by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050011
Actively Recruiting
Research Team
C
Cuizhi Geng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here